GILEAD SCIENCES INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Jacqueline K. Barton, Ph.D.”): 995,391,975 for, 12,399,781 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 200 managers: 502,519,389 for, 35,670 against, 480,620 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 11 managers: 17,477,733 for, 2,730 against, 446 unknown.

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Jeffrey A. Bluestone, Ph.D.”): 1,000,314,606 for, 7,419,797 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 211 asset managers below reported 502,701,106 for, 10,603 against, 480,624 abstained.

Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Sandra J. Horning, M.D.”): 985,486,994 for, 22,304,826 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 211 asset managers below reported 502,339,428 for, 372,285 against, 480,620 abstained.

Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Kelly A. Kramer”): 980,895,123 for, 26,851,069 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 211 asset managers below reported 502,611,152 for, 100,113 against, 480,623 abstained, 446 unknown.

Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish Manwani

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Harish Manwani”): 968,115,418 for, 39,518,665 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 211 asset managers below reported 500,239,291 for, 2,471,968 against, 480,628 abstained, 446 unknown.

Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'Day

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Daniel P. O'Day”): 939,111,309 for, 63,134,940 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 211 asset managers below reported 502,138,595 for, 572,747 against, 480,991 abstained.

Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Javier J. Rodriguez”): 1,000,194,729 for, 7,506,046 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 211 asset managers below reported 502,681,770 for, 29,937 against, 480,626 abstained.

Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony Welters

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Anthony Welters”): 932,173,164 for, 75,508,127 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 211 asset managers below reported 487,032,963 for, 15,678,297 against, 480,627 abstained, 446 unknown.

Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.

GILEAD SCIENCES INC.’s own tally for this item (“Elect Director: Ted W. Love, M.D.”): 1,002,644,132 for, 5,021,345 against, per its Form 8-K filed May 9, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 210 asset managers below reported 502,707,871 for, 333 against, 480,628 abstained.

Showing the 25 largest of 210 asset managers. See all 210 in the interactive database.

Description as filed by funds: To vote on a stockholder proposal requesting that the Board include one member from the Company's non-management employees.

GILEAD SCIENCES INC.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting that the Board include one member from the Company's non-management employees. The proposal received the following votes:”): 59,235,065 for, 946,161,838 against — failed, per its Form 8-K filed May 9, 2024 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting that the Board include one member from the Company's non-management employees.”
Support: 6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of GILEAD SCIENCES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Adopt a Policy to Include Non-Management Employees as Prospective Director Candidates” (11 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 201 asset managers below reported 4,054,511 for, 445,858,322 against, 620,950 abstained, 446 unknown.

Showing the 25 largest of 201 asset managers. See all 201 in the interactive database.

Description as filed by funds: To approve an amendment to our Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.

GILEAD SCIENCES INC.’s own tally for this item (“The Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. The proposal received the following votes:”): 905,468,022 for, 101,692,634 against — passed, per its Form 8-K filed May 9, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of GILEAD SCIENCES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Approve Charter Amendment” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 212 asset managers below reported 481,226,023 for, 21,769,519 against, 482,724 abstained.

Showing the 25 largest of 212 asset managers. See all 212 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement

GILEAD SCIENCES INC.’s own tally for this item (“The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:”): 928,702,915 for, 78,647,808 against — passed, per its Form 8-K filed May 9, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 202 managers: 501,283,382 for, 1,319,075 against, 480,648 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1,059 managers: 613,085,431 for, 48,474,643 against, 11,869 withheld, 18,533 abstained, 27,280 not voted, 958,080 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

GILEAD SCIENCES INC.’s own tally for this item (“The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposal received the following vote”): 1,039,381,050 for, 74,100,517 against — passed, per its Form 8-K filed May 9, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of GILEAD SCIENCES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (4 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 210 asset managers below reported 501,698,921 for, 1,074,345 against, 480,613 abstained, 446 unknown.

Showing the 25 largest of 210 asset managers. See all 210 in the interactive database.

Description as filed by funds: To vote on a stockholder proposal requesting that the Board adopt a policy requiring the Company's named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age 60).

GILEAD SCIENCES INC.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting that the Board adopt a policy requiring the Company's named executive officers to retain at least 25% of net-after tax shares of stock acquired”): 361,356,676 for, 645,764,310 against — failed, per its Form 8-K filed May 9, 2024 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting that the Board adopt a policy requiring the Company's named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age…”
Support: 36% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of GILEAD SCIENCES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Shareholder Proposal Regarding Retention of Shares Until Normal Retirement Age” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 200 managers: 69,755,040 for, 432,823,599 against, 480,664 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 28 managers: 480,149 for, 126,221 against, 5,744,694 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To vote on a stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company may deploy to minimize or mitigate these risks.

GILEAD SCIENCES INC.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response ”): 17,930,954 for, 977,168,730 against — failed, per its Form 8-K filed May 9, 2024 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond liti…”
Support: 2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 211 asset managers below reported 2,020,373 for, 498,552,844 against, 3,220,853 abstained, 446 unknown.

Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.